Stifel’s Biopharmaceutical Outlook for 2025 and review of 2024 reveals the challenges for the biotech market as we start the year. DealForma data highlights the trends in licensing, M&A, and investment. Definitely an important weekly report from Tim Opler and team. Read the article here
